Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Melvin Yahr
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Disorders
Living Beings
Anatomy
Procedures
Sign-in to see full Profile
Network (preview)
22
Brannan, T
10
Prikhojan, Alexander
9
Di Rocco, Alessandro
6
Kaufmann, Horacio
3
Cohen, G
3
Bodis-Wollner, Ivan
3
Mytilineou, Catherine
2
Saadia, Daniela
2
Borod, Joan
2
Knott, PJ
1
Drayer, Burton
1
Goldstein, David
1
Bottiglieri, T
1
Sliwinski, Martin
1
Voustianiouk, Andrei
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Melvin Yahr (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2005: Mazzella L; Yahr M D; Marinelli L; Huang N; Moshier E; Di Rocco A
Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
Parkinsonism & related disorders 2005;11(3):151-5.
-
2004: Gluck M R; Santana L A; Granson H; Yahr M D
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
Journal of neural transmission (Vienna, Austria : 1996) 2004;111(6):713-24.
-
2003: Kaufmann Horacio; Saadia Daniela; Voustianiouk Andrei; Goldstein David S; Holmes Courtney; Yahr Melvin D; Nardin Rachel; Freeman Roy
Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
Circulation 2003;108(6):724-8.
-
2003: Yahr M D; Orosz D; Purohit D P
Co-occurrence of essential tremor and Parkinson's disease: clinical study of a large kindred with autopsy findings.
Parkinsonism & related disorders 2003;9(4):225-31.
-
2003: Bhattacharya K F; Nouri S; Olanow C W; Yahr M D; Kaufmann H
Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension.
Parkinsonism & related disorders 2003;9(4):221-4.
-
2002: Prikhojan A; Brannan T; Yahr M D
Intrastriatal iron perfusion releases dopamine: an in-vivo microdialysis study.
Journal of neural transmission (Vienna, Austria : 1996) 2002;109(5-6):645-9.
-
2002: Bhattacharya Kirsty; Saadia Daniela; Eisenkraft Barbara; Yahr Melvin; Olanow Warren; Drayer Burton; Kaufmann Horacio
Brain magnetic resonance imaging in multiple-system atrophy and Parkinson disease: a diagnostic algorithm.
Archives of neurology 2002;59(5):835-42.
-
2001: Werner P; Di Rocco A; Prikhojan A; Rempel N; Bottiglieri T; Bressman S; Yahr M D
COMT-dependent protection of dopaminergic neurons by methionine, dimethionine and S-adenosylmethionine (SAM) against L-dopa toxicity in vitro.
Brain research 2001;893(1-2):278-81.
-
2000: Prikhojan A; Brannan T; Yahr M D
Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.
Journal of neural transmission (Vienna, Austria : 1996) 2000;107(10):1159-64.
-
1999: Brannan T; Yahr M D
Focal tremor following striatal infarct--a case report.
Movement disorders : official journal of the Movement Disorder Society 1999;14(2):368-70.
-
1998: Brannan T; Prikhojan A; Yahr M D
Effects of repeated administration of l-DOPA and apomorphine on circling behavior and striatal dopamine formation.
Brain research 1998;784(1-2):148-53.
-
1998: Casals J; Elizan T S; Yahr M D
Postencephalitic parkinsonism--a review.
Journal of neural transmission (Vienna, Austria : 1996) 1998;105(6-7):645-76.
-
1998: Di Rocco A; Brannan T; Prikhojan A; Yahr M D
Sertraline induced parkinsonism. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism.
Journal of neural transmission (Vienna, Austria : 1996) 1998;105(2-3):247-51.
-
1997: Brannan T; Prikhojan A; Yahr M D
Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
Journal of neural transmission (Vienna, Austria : 1996) 1997;104(1):77-87.
-
1996: Brannan T; Prikhojan A; Yahr M D
Elevated striatal dopamine levels following administration of D-DOPA and its alpha-keto acid metabolite DHPPA: behavioral and physiological studies in vivo in the rat.
Brain research 1996;718(1-2):165-8.
-
1996: Molinari S P; Di Rocco A; Merchant C; Sen C N; Wolfe D; Yahr M D
An unusual sphenoid ridge tumor: cementifying fibroma.
Journal of neurology 1996;243(1):103-4.
-
1996: Brannan T; Prikhojan A; Yahr M D
An in vivo comparison of the capacity of striatal versus extrastriatal brain regions to form dopamine from exogenously administered L-dopa.
Journal of neural transmission (Vienna, Austria : 1996) 1996;103(11):1287-94.
-
1996: Di Rocco A; Molinari S P; Kollmeier B; Yahr M D
Parkinson's disease: progression and mortality in the L-DOPA era.
Advances in neurology 1996;69():3-11.
-
1995: Molinari S P; Sivakumar K; Corbin D; Yahr M D
Central neurocytoma: An unusual intraventricular tumor.
The Mount Sinai journal of medicine, New York 1995;62(6):436-8.
-
1995: Brannan T; Yahr M D
Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
Annals of neurology 1995;37(1):95-8.
-
1995: Brannan T; Prikhojan A; Martínez-Tica J; Yahr M D
In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.
Journal of neural transmission. Parkinson's disease and dementia section 1995;10(2-3):79-89.
-
1995: Molinari S P; Kaminski R; Di Rocco A; Yahr M D
The use of famotidine in the treatment of Parkinson's disease: a pilot study.
Journal of neural transmission. Parkinson's disease and dementia section 1995;9(2-3):243-7.
-
1995: Merchant C A; Cohen G; Mytilineou C; DiRocco A; Moros D; Molinari S; Yahr M D
Human transplacental transfer of carbidopa/levodopa.
Journal of neural transmission. Parkinson's disease and dementia section 1995;9(2-3):239-42.
-
1995: Bodis-Wollner I; Borod J C; Cicero B; Haywood C S; Raskin S; Mylin L; Sliwinski M; Falk A; Yahr M D
Modality dependent changes in event-related potentials correlate with specific cognitive functions in nondemented patients with Parkinson's disease.
Journal of neural transmission. Parkinson's disease and dementia section 1995;9(2-3):197-209.
-
1994: Werner P; Mytilineou C; Cohen G; Yahr M D
Impaired oxidation of pyruvate in human embryonic fibroblasts after exposure to L-dopa.
European journal of pharmacology 1994;263(1-2):157-62.
-
1994: Brannan T; Prikhojan A; Yahr M D
Effect of a selective MAO-A inhibitor (Ro 41-1049) on striatal L-dopa and dopamine metabolism: an in vivo study.
Journal of neural transmission. Parkinson's disease and dementia section 1994;8(1-2):99-105.
-
1994: Mytilineou C; Werner P; Molinari S; Di Rocco A; Cohen G; Yahr M D
Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease.
Journal of neural transmission. Parkinson's disease and dementia section 1994;8(3):223-8.
-
1993: Yahr M D
Parkinson's disease. The L-dopa era.
Advances in neurology 1993;60():11-7.
-
1993: Yahr M D
Parkinson's disease: new approaches to diagnosis and treatment.
Acta neurologica Scandinavica. Supplementum 1993;146():22-5.
-
1993: Di Rocco A; Molinari S; Stollman A L; Decker A; Yahr M D
MRI abnormalities in Creutzfeldt-Jakob disease.
Neuroradiology 1993;35(8):584-5.
-
1993: Brannan T; Martínez-Tica J; Yahr M D
Effect of repeated electroconvulsive shock on striatal L-dopa and dopamine metabolism: an in vivo study.
Journal of neural transmission. Parkinson's disease and dementia section 1993;6(1):35-44.
-
1993: Brannan T; Martínez-Tica J; Di Rocco A; Yahr M D
Low and high dose bromocriptine have different effects on striatal dopamine release: an in vivo study.
Journal of neural transmission. Parkinson's disease and dementia section 1993;6(2):81-7.
-
1992: Brannan T; Martínez-Tica J; Yahr M D
Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats.
Neurology 1992;42(3 Pt 1):683-5.
-
1992: Kaufmann H; Oribe E; Miller M; Knott P; Wiltshire-Clement M; Yahr M D
Hypotension-induced vasopressin release distinguishes between pure autonomic failure and multiple system atrophy with autonomic failure.
Neurology 1992;42(3 Pt 1):590-3.
-
1992: Brannan T; Martínez-Tica J; Yahr M D
Changes in body temperature markedly affect striatal dopamine release and metabolism: an in vivo study.
Journal of neural transmission. General section 1992;89(3):193-6.
-
1991: Brannan T; Martinez-Tica J; Yahr M D
Effect of dietary protein on striatal dopamine formation following L-dopa administration: an in vivo study.
Neuropharmacology 1991;30(10):1125-7.
-
1991: Brannan T; Martinez-Tica J; Yahr M D
Effect of long-term L-dopa administration on striatal extracellular dopamine release.
Neurology 1991;41(4):596-8.
-
1991: Elizan T S; Moros D A; Yahr M D
Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months.
Archives of neurology 1991;48(1):31-4.
-
1991: Kaufmann H; Oribe E; Yahr M D
Differential effect of L-threo-3,4-dihydroxyphenylserine in pure autonomic failure and multiple system atrophy with autonomic failure.
Journal of neural transmission. Parkinson's disease and dementia section 1991;3(2):143-8.
-
1991: Brannan T; Martinez-Tica J; Yahr M D
Effect of yohimbine on brain monoamines: an in vivo study.
Journal of neural transmission. Parkinson's disease and dementia section 1991;3(2):81-7.
-
1990: Kaufmann H; Oribe E; Pierotti A R; Roberts J L; Yahr M D
Atrial natriuretic factor in human autonomic failure.
Neurology 1990;40(7):1115-9.
-
1990: Brannan T; Bhardwaj A; Yahr M D
L-threodops increases extracellular norepinephrine levels in the brain: an in vivo study.
Neurology 1990;40(7):1134-5.
-
1990: Brannan T; Knott P; Kaufmann H; Yahr M
In vivo studies of striatal dopamine release and metabolism following administration of L-dopa.
Advances in neurology 1990;53():75-81.
-
1990: Elizan T S; Yahr M D; Moros D A; Mendoza M R; Pang S; Bodian C A
L-deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-dopa therapy in Parkinson's disease: experience in 200 patients.
Advances in neurology 1990;53():431-5.
-
1990: Brannan T; Bhardwaj A; Martinez-Tica J; Weinberger J; Yahr M
Striatal L-dopa metabolism studied in vivo in rats with nigrostriatal lesions.
Journal of neural transmission. Parkinson's disease and dementia section 1990;2(1):15-22.
-
1990: Pang S; Borod J C; Hernandez A; Bodis-Wollner I; Raskin S; Mylin L; Coscia L; Yahr M D
The auditory P 300 correlates with specific cognitive deficits in Parkinson's disease.
Journal of neural transmission. Parkinson's disease and dementia section 1990;2(4):249-64.
-
1989: Elizan T S; Yahr M D; Moros D A; Mendoza M R; Pang S; Bodian C A
Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
Archives of neurology 1989;46(12):1280-3.
-
1989: Elizan T S; Yahr M D; Moros D A; Mendoza M R; Pang S; Bodian C A
Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients.
Archives of neurology 1989;46(12):1275-9.
-
1989: Brannan T; Knott P; Kaufmann H; Leung L; Yahr M
Intracerebral dialysis monitoring of striatal dopamine release and metabolism in response to L-dopa.
Journal of neural transmission 1989;75(2):149-57.
-
1989: Yahr M D; Elizan T S; Moros D
Selegiline in the treatment of Parkinson's disease--long term experience.
Acta neurologica Scandinavica. Supplementum 1989;126():157-61.
-
1989: Lee D H; Mendoza M; Dvorozniak M T; Chung E; van Woert M H; Yahr M D
Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy.
Journal of neural transmission. Parkinson's disease and dementia section 1989;1(3):189-94.
-
1988: Dickoff D J; Raps M; Yahr M D
Striatal syndrome following hyponatremia and its rapid correction. A manifestation of extrapontine myelinolysis confirmed by magnetic resonance imaging.
Archives of neurology 1988;45(1):112-4.
-
1987: Bodis-Wollner I; Marx M S; Mitra S; Bobak P; Mylin L; Yahr M
Visual dysfunction in Parkinson's disease. Loss in spatiotemporal contrast sensitivity.
Brain : a journal of neurology 1987;110 ( Pt 6)():1675-98.
-
1987: Yahr M D
R-(-)-deprenyl and parkinsonism.
Journal of neural transmission. Supplementum 1987;25():5-12.
-
1987: Bergmann K J; Mendoza M R; Yahr M D
Parkinson's disease and long-term levodopa therapy.
Advances in neurology 1987;45():463-7.
-
1986: Elizan T S; Sroka H; Maker H; Smith H; Yahr M D
Dementia in idiopathic Parkinson's disease. Variables associated with its occurrence in 203 patients.
Journal of neural transmission 1986;65(3-4):285-302.
-
1984: Moros D A; Yahr M D
Movement disorders in the psychiatric patient.
Hospital & community psychiatry 1984;35(4):377-83.
-
1984: Bergmann K J; Limongi J C; Lowe Y H; Mendoza M R; Yahr M D
Potentiation of the "dopa" effect in parkinsonism by a direct GABA receptor agonist.
Lancet 1984;1(8376):559.
-
1984: Clough C G; Bergmann K J; Yahr M D
Cholinergic and dopaminergic mechanisms in Parkinson's disease after long-term L-DOPA administration.
Advances in neurology 1984;40():131-40.
-
1983: Elizan T S; Casals J; Yahr M D
Antineurofilament antibodies in postencephalitic and idiopathic Parkinson's disease.
Journal of the neurological sciences 1983;59(3):341-7.
-
1983: Yahr M D; Mendoza M R; Moros D; Bergmann K J
Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline).
Acta neurologica Scandinavica. Supplementum 1983;95():95-102.
-
1983: Elizan T S; Maker H; Yahr M D
Neurotransmitter synthesizing enzymes in experimental viral encephalitis.
Journal of neural transmission 1983;57(3):139-47.
-
1982: Yahr M D; Clough C G; Bergmann K J
Cholinergic and dopaminergic mechanisms in Parkinson's disease after long term levodopa administration.
Lancet 1982;2(8300):709-10.
-
1981: Sroka H; Elizan T S; Yahr M D; Burger A; Mendoza M R
Organic mental syndrome and confusional states in Parkinson's disease. Relationship to computerized tomographic signs of cerebral atrophy.
Archives of neurology 1981;38(6):339-42.
Sign-in to see more
